Moleculin Biotech (NASDAQ:MBRX) Earns Buy Rating from HC Wainwright

Moleculin Biotech (NASDAQ:MBRX)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $8.00 price objective on the stock.

Other equities analysts have also issued reports about the stock. Maxim Group lowered shares of Moleculin Biotech from a “buy” rating to a “hold” rating in a report on Wednesday, February 12th. StockNews.com began coverage on Moleculin Biotech in a research note on Thursday, March 13th. They set a “sell” rating for the company.

Moleculin Biotech Trading Up 8.5 %

Shares of Moleculin Biotech stock opened at $1.15 on Monday. Moleculin Biotech has a 1 year low of $0.40 and a 1 year high of $6.23. The company has a 50-day moving average of $1.33 and a 200 day moving average of $2.00.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs.